Fibrobiologics Inc (FBLG)

$0.26 +0.00 (1.42%)
Market Cap 14.05M
Revenue (ttm) 0.00
Net Income (ttm) -11.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 35.15
Volume 1,492,700
Avg Vol 1,296,154
Day's Range N/A - N/A
Shares Out 53.28M
Stochastic %K 47%
Beta -0.58
Analysts Strong Sell
Price Target $8.75

Company Profile

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The company was founded in 2021 and is based in Houston, Texas.

Industry: Biotechnology
Sector: Healthcare
Phone: 281-651-5150
Address:
455 East Medical Center Boulevard, Suite 300, Houston, United States
McMillion1
McMillion1 Dec. 5 at 11:41 AM
$FBLG $3
0 · Reply
SPYmyQQQ
SPYmyQQQ Dec. 4 at 3:25 PM
🚀 New Signal ✅ 💊 $FBLG 🗓️ Dec 4, 2025 💵 Entry: $0.2550 🎯 Target (Opt.): $0.2958 (+16.00%) 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
Shortsalwayswin
Shortsalwayswin Dec. 4 at 1:09 PM
$FBLG new all time lows again today
0 · Reply
Shortsalwayswin
Shortsalwayswin Dec. 3 at 4:16 PM
$FBLG next big drop early next week to around 18 cents
0 · Reply
Shortsalwayswin
Shortsalwayswin Dec. 1 at 8:03 PM
$FBLG Yes it is
0 · Reply
dvdfnn
dvdfnn Nov. 28 at 4:11 PM
$SMX $FBLG FBLG Gold paid offering
1 · Reply
PaulLaurent
PaulLaurent Nov. 27 at 7:55 PM
🚫📉 Zero Borrow Stocks (Excluding Naked Shorts) 💥🚫 $SPXD $SAEF $FBLG $PLRZ $BRR
3 · Reply
RPGinbound
RPGinbound Nov. 26 at 1:39 PM
$FBLG Was almost excited, until tou realize theres millions more they can raise, and that the debt was paid off at the expense of diluting current holders. Death Spiral Financing rings a bell…GL
0 · Reply
Skiman0
Skiman0 Nov. 25 at 7:22 PM
$FBLG is this going to zero ?
0 · Reply
Zen69
Zen69 Nov. 25 at 12:25 AM
$FBLG now have cash to work + 6month and institutionnel average buy is 0.335 wait next catalyst to run 1$ or more NFA DYOR
0 · Reply
Latest News on FBLG
FibroBiologics Announces Payoff of Outstanding Debt

Nov 26, 2025, 8:30 AM EST - 11 days ago

FibroBiologics Announces Payoff of Outstanding Debt

FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 25, 2025, 4:05 PM EST - 11 days ago

FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 24, 2025, 9:00 AM EST - 13 days ago

FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

Nov 20, 2025, 8:00 AM EST - 17 days ago

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 19, 2025, 7:03 PM EST - 17 days ago

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 19, 2025, 8:36 AM EST - 18 days ago

FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 31, 2025, 4:30 PM EDT - 5 weeks ago

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics to Present at Bio-Europe 2025

Oct 24, 2025, 8:30 AM EDT - 6 weeks ago

FibroBiologics to Present at Bio-Europe 2025

FibroBiologics to Present at the 2025 ThinkEquity Conference

Oct 14, 2025, 8:30 AM EDT - 7 weeks ago

FibroBiologics to Present at the 2025 ThinkEquity Conference

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

Sep 23, 2025, 8:30 AM EDT - 2 months ago

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

Sep 12, 2025, 8:30 AM EDT - 3 months ago

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

Sep 11, 2025, 8:30 AM EDT - 3 months ago

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies

Sep 10, 2025, 8:30 AM EDT - 3 months ago

FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies

FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 8:30 AM EDT - 3 months ago

FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 31, 2025, 4:30 PM EDT - 4 months ago

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

Jul 28, 2025, 8:30 AM EDT - 4 months ago

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

FibroBiologics to Present at the Advanced Wound Care Summit USA

Jul 11, 2025, 8:30 AM EDT - 5 months ago

FibroBiologics to Present at the Advanced Wound Care Summit USA

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank

Jul 9, 2025, 8:30 AM EDT - 5 months ago

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank

FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

Jul 7, 2025, 4:35 PM EDT - 5 months ago

FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

Jun 16, 2025, 4:35 PM EDT - 6 months ago

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

FibroBiologics to Present at the BIO International Convention 2025

Jun 16, 2025, 9:50 AM EDT - 6 months ago

FibroBiologics to Present at the BIO International Convention 2025

FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

Jun 9, 2025, 8:30 AM EDT - 6 months ago

FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

May 16, 2025, 8:30 AM EDT - 7 months ago

FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:30 PM EDT - 7 months ago

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics Presenting at the ThymUS 2025 Meeting

Apr 29, 2025, 9:15 AM EDT - 7 months ago

FibroBiologics Presenting at the ThymUS 2025 Meeting

FibroBiologics Presents at the ThymUS 2025 Meeting

Apr 29, 2025, 9:15 AM EDT - 7 months ago

FibroBiologics Presents at the ThymUS 2025 Meeting

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

Apr 11, 2025, 8:30 AM EDT - 8 months ago

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics

Apr 8, 2025, 8:30 AM EDT - 8 months ago

FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics

FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair

Apr 2, 2025, 8:30 AM EDT - 8 months ago

FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair

FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 31, 2025, 4:25 PM EDT - 8 months ago

FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update

FibroBiologics Announces 2025 Annual Meeting of Stockholders

Mar 27, 2025, 8:30 AM EDT - 9 months ago

FibroBiologics Announces 2025 Annual Meeting of Stockholders

FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting

Mar 21, 2025, 8:30 AM EDT - 9 months ago

FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting

FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics

Mar 4, 2025, 8:30 AM EST - 9 months ago

FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics

FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic

Feb 27, 2025, 8:30 AM EST - 10 months ago

FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic

FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates

Feb 5, 2025, 9:15 AM EST - 10 months ago

FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates

FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing

Dec 30, 2024, 4:30 PM EST - 1 year ago

FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing

D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing

Dec 30, 2024, 2:12 PM EST - 1 year ago

D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing

FibroBiologics Announces $25 Million Financing

Dec 23, 2024, 7:55 AM EST - 1 year ago

FibroBiologics Announces $25 Million Financing

FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly

Nov 19, 2024, 9:15 AM EST - 1 year ago

FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly

FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics

Nov 14, 2024, 9:15 AM EST - 1 year ago

FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics

FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 12, 2024, 4:20 PM EST - 1 year ago

FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology

Oct 29, 2024, 9:15 AM EDT - 1 year ago

FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology

FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024

Oct 28, 2024, 9:31 AM EDT - 1 year ago

FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024

FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases

Oct 18, 2024, 8:30 AM EDT - 1 year ago

FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases

FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office

Oct 16, 2024, 9:15 AM EDT - 1 year ago

FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office

FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit

Oct 11, 2024, 9:31 AM EDT - 1 year ago

FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit

FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa

Sep 30, 2024, 9:31 AM EDT - 1 year ago

FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa

FibroBiologics Engages Southern Star Research as CRO in Australia

Sep 19, 2024, 9:31 AM EDT - 1 year ago

FibroBiologics Engages Southern Star Research as CRO in Australia

FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology

Sep 12, 2024, 9:31 AM EDT - 1 year ago

FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology

FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 6, 2024, 9:31 AM EDT - 1 year ago

FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

McMillion1
McMillion1 Dec. 5 at 11:41 AM
$FBLG $3
0 · Reply
SPYmyQQQ
SPYmyQQQ Dec. 4 at 3:25 PM
🚀 New Signal ✅ 💊 $FBLG 🗓️ Dec 4, 2025 💵 Entry: $0.2550 🎯 Target (Opt.): $0.2958 (+16.00%) 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
Shortsalwayswin
Shortsalwayswin Dec. 4 at 1:09 PM
$FBLG new all time lows again today
0 · Reply
Shortsalwayswin
Shortsalwayswin Dec. 3 at 4:16 PM
$FBLG next big drop early next week to around 18 cents
0 · Reply
Shortsalwayswin
Shortsalwayswin Dec. 1 at 8:03 PM
$FBLG Yes it is
0 · Reply
dvdfnn
dvdfnn Nov. 28 at 4:11 PM
$SMX $FBLG FBLG Gold paid offering
1 · Reply
PaulLaurent
PaulLaurent Nov. 27 at 7:55 PM
🚫📉 Zero Borrow Stocks (Excluding Naked Shorts) 💥🚫 $SPXD $SAEF $FBLG $PLRZ $BRR
3 · Reply
RPGinbound
RPGinbound Nov. 26 at 1:39 PM
$FBLG Was almost excited, until tou realize theres millions more they can raise, and that the debt was paid off at the expense of diluting current holders. Death Spiral Financing rings a bell…GL
0 · Reply
Skiman0
Skiman0 Nov. 25 at 7:22 PM
$FBLG is this going to zero ?
0 · Reply
Zen69
Zen69 Nov. 25 at 12:25 AM
$FBLG now have cash to work + 6month and institutionnel average buy is 0.335 wait next catalyst to run 1$ or more NFA DYOR
0 · Reply
HighSierras
HighSierras Nov. 24 at 4:18 PM
$FBLG https://finance.yahoo.com/news/fibrobiologics-announces-1-5-million-140000015.html
0 · Reply
stockanalysis_
stockanalysis_ Nov. 24 at 2:48 PM
Losers Today: $CLSD $DDC $TWNP $PMN $FBLG Bookmark this page: https://stockanalysis.com/markets/losers/?ref=saveontrading
0 · Reply
Shortsalwayswin
Shortsalwayswin Nov. 21 at 3:59 PM
$FBLG this next drop is going to be very ugly
2 · Reply
Shortsalwayswin
Shortsalwayswin Nov. 20 at 9:32 PM
$FBLG 15 cents maybe
0 · Reply
Shortsalwayswin
Shortsalwayswin Nov. 20 at 8:49 PM
$FBLG back down to 23 cents
0 · Reply
Shortsalwayswin
Shortsalwayswin Nov. 20 at 8:08 PM
$FBLG buy mid day at the bottom and sell during AH/PM 15% swing every single day. Same pattern every single day
0 · Reply
Peace2026
Peace2026 Nov. 20 at 8:04 PM
$FBLG https://www.gurufocus.com/news/3218205/fibrobiologics-fblg-analyst-ratings-d-boral-capital-maintains-buy-fblg-stock-news
0 · Reply
peepthestamp
peepthestamp Nov. 20 at 2:48 PM
$FBLG $CAN $DVLT $KOS
0 · Reply
RPGinbound
RPGinbound Nov. 20 at 1:31 PM
$FBLG Watch alerted. Funding/dilution over and investor got in basically at current SP. Vol a clue. Concentrate on social media focus. GL
0 · Reply
JarvisFlow
JarvisFlow Nov. 20 at 1:08 PM
D. Boral Capital updates rating for FibroBiologics ( $FBLG ) to Buy, target set at 15.
0 · Reply
BigPennyStockAlerts
BigPennyStockAlerts Nov. 20 at 1:03 PM
$FBLG- $0.36 FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
0 · Reply